Medical research explains that GLP-1-associated hair loss is unique because the continued weight loss creates an ongoing stressor
For example, policies with in-patient-only benefits would be expected to have limited exposure to GLP-1 utilization because these drugs are mainly prescribed in the outpatient setting
However, these investigational findings do not establish approval, general suitability, or long-term safety
p38beta Mitogen- activated protein kinase signaling mediates exenatide-stimulated microglial beta-endorphin expression
GLP-1 agonists slow gastric emptying and reduce appetite
As an illustration, prices range from over USD 12,000 per year for GLP-1 obesity drugs to USD 2.2 million for a one-off genetic cure for hereditary blood disorders in the US, underscoring an emerging tension between medical progress and financial sustainability